GlassScriptPhysician profile
Jonathan P Greenblatt
NPI 1912960568
$14,213.65
in general payments reported to CMS, 2019-2025
32 companies · $929 in 2025
The $929 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $59.69 · 2021: $13.59 · 2022: $255 · 2023: $298 · 2024: $541 · 2025: $929.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,768.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,768.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $8,677.01 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $3,119.81 | 2019-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $225.91 | 2019-2025 | Wainua, Farxiga |
| Abbott Laboratories | $186.87 | 2023-2024 | Mitraclip, Ensite |
| Janssen Pharmaceuticals, INC | $156.51 | 2019-2024 | Xarelto |
| Boston Scientific Corporation | $156.29 | 2019-2024 | Lux-Dx Insertable Cardiac Monitor |
| Pfizer INC. | $149.27 | 2020-2025 | |
| Actelion Pharmaceuticals US, INC. | $142.70 | 2019-2025 | Uptravi, Opsumit |
| Novartis Pharmaceuticals Corporation | $139.53 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $125.00 | 2023 | Dupixent |
| Shockwave Medical, INC | $124.70 | 2022 | |
| Amgen INC. | $107.97 | 2019-2025 | Repatha, Repatha |
| Lexicon Pharmaceuticals, INC. | $91.51 | 2025 | |
| Cvrx, INC. | $88.91 | 2024-2025 | Barostim Neo System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $83.52 | 2019-2025 | Jardiance |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $71.16 | 2024-2025 | Verquvo |
| Kiniksa Pharmaceuticals International, Plc | $64.47 | 2024 | Arcalyst |
| Heartflow, INC. | $53.75 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $51.96 | 2025 | |
| Medtronic, INC. | $49.04 | 2021-2022 | |
| Abiomed | $43.57 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.40 | 2024-2025 | Xifaxan |
| Esperion Therapeutics, INC. | $42.08 | 2024-2025 | Nexletol |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $33.72 | 2019 | |
| Novo Nordisk INC | $32.00 | 2024-2025 | Wegovy, Rybelsus, Ozempic |
| Bridgebio Pharma, INC. | $29.27 | 2025 | Attruby |
| Edwards Lifesciences Corporation | $25.59 | 2024 | |
| United Therapeutics Corporation | $25.50 | 2025 | Tyvaso |
| Tactile Systems Technology INC | $24.31 | 2025 | Nimbl, Flexitouch Plus |
| Atricure, INC. | $23.19 | 2025 | Epi-Sense Guided Coagulation System With Visitrax |
| Sanofi-Aventis U.S. LLC | $14.20 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $10.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Greenblatt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.